Titan Biotech Ltd has closed its trading window for all designated persons effective Wednesday, July 1, 2026. The window will remain shut until 48 hours after the company declares its unaudited financial results for the quarter ended June 30, 2026. This measure is implemented to comply with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct for preventing insider trading.

The restriction covers securities of the company and applies to all directors, promoters, key managerial personnel (KMPs), other designated persons, employees, and their immediate relatives. The closure ensures that no insider trading occurs while the financial results for Q1FY26 are being finalized and prepared for public disclosure.

The company stated that the specific date for the board meeting to declare the unaudited financial results for the quarter ended June 30, 2026, will be intimated in due course. Once the results are announced to the stock exchange and made public, the trading window will reopen 48 hours later.

The communication was addressed to the Corporate Services Department of BSE Ltd. The filing was signed by Charanjit Singh, Company Secretary and Compliance Officer of Titan Biotech Ltd, on June 23, 2026.

Titan Biotech reported a 50.20% year-on-year increase in net profit to ₹2,744.72 lakh for the financial year ended March 31, 2026. Revenue from operations for the year rose to ₹20,619.03 lakh from ₹15,645.08 lakh in the previous year, while total income increased to ₹21,160.05 lakh. The Board of Directors has recommended a dividend of ₹0.50 per equity share, subject to approval by shareholders at the ensuing Annual General Meeting.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹655.57 lakh, compared to ₹376.61 lakh in the corresponding period of the previous year. Revenue from operations for the quarter stood at ₹4,883.35 lakh, against ₹3,520 lakh in the year-ago period. Q4 EBITDA came in at 97M rupees, compared to 46M rupees in the same quarter of the previous year, with the EBITDA margin expanding to 19.89% from 12.99% year-on-year. The statutory auditors, A N S K & Associates, issued an unmodified opinion on the standalone and consolidated financial results.

Financial Performance

The company's total expenses for FY26 amounted to ₹17,342.60 lakh, up from ₹13,599.60 lakh in the prior year. Profit before tax for the year was ₹3,817.45 lakh, a significant increase from ₹2,436.73 lakh in FY25. Basic earnings per share for the year improved to ₹6.64 from ₹4.42 in the previous year. The following table summarises the full-year and quarterly standalone financial highlights:

The quarterly performance further highlights the company's improving profitability trajectory, with Q4 EBITDA margin expanding significantly on a year-on-year basis:

Corporate Actions

The Board of Directors, in its meeting held on May 30, 2026, approved the re-appointment of M/s Sanjay Kumar Garg & Associates as Cost Auditor for FY27. The appointment is subject to the ratification of remuneration by shareholders at the ensuing Annual General Meeting. The firm's registration number is 100292. Additionally, the board appointed Mr. Pankaj Kumar Gupta as the scrutinizer for the 34th Annual General Meeting to be held in 2026. The subdivision of equity shares from a face value of ₹10 to ₹2 each was effective from February 20, 2026.

Consolidated Results

On a consolidated basis, the company reported a net profit of ₹2,988.52 lakh for FY26, compared to ₹2,153.16 lakh in the previous year. The consolidated results include the financials of associate companies Peptech Biosciences Limited and Titan Media Limited. Total comprehensive income for the year stood at ₹2,979.70 lakh.